For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

From radiopharmaceuticals to hypofractionated radiation therapy, one expert explained the current landscape of radiation treatments for prostate cancer. Radiopharmaceuticals, defined by the National ...

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

If you have prostate cancer and radiation therapy is an option, how to choose which type is right for your situation? The answer lies in a discussion with your doctor about the pluses and minuses of ...

SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...

Researchers found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, is as safe as conventional treatment, with similar side effects and a ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...

Impact of antiresorptive bone agents in hormone-sensitive metastatic prostate cancer (mHSPC): A meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Outcomes for 177Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.